Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | CCR3 | P51677 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8302417 | 0.83 | OPRM1 (0.51) | CCR3CARM1PRMT6ACHE | |
| SCHEMBL13185171 | 0.83 | HTR2A (0.49) | CCR3BRD9CARM1PRMT6ACHE | |
| SCHEMBL23026277 | 0.82 | MAOB (0.47) | CARM1PRMT6 | |
| SCHEMBL1119520 | 0.82 | SLC6A2 (0.46) | SLC6A2SLC6A4CCR3ATM | |
| SCHEMBL4040585 | 0.81 | LMNA (0.53) | CCR3BRD9CARM1PRMT6PRMT3 | |
| SCHEMBL8302415 | 0.81 | OPRM1 (0.51) | — | |
| SCHEMBL21443558 | 0.81 | CCR3 (0.45) | CCR3CCR5BRD9CARM1PRMT6 | |
| SCHEMBL2056158 | 0.81 | ALDH1A1 (0.61) | SLC6A2SLC6A4CCR3 | |
| SCHEMBL327856 | 0.81 | CCR3 (0.66) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL23655069 | 0.81 | SLC6A2 (0.46) | SLC6A2SLC6A4CCR3CHRM2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | disclosed |
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2011123946-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| CN-102119163-A | Diazacarbazoles and methods of use | GENENTECH INC | 2011-07-06 | — | — | CN | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300475-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | SLC6A2 4681/4885SLC6A4 4720/4885CCR3 961/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | SLC6A2 4194/4885SLC6A4 4011/4885CCR3 4504/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | SLC6A2 4194/4885SLC6A4 4011/4885CCR3 4504/4885 |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | SLC6A2 2892/4885SLC6A4 4040/4885CCR3 1857/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | SLC6A2 4194/4885SLC6A4 4011/4885CCR3 4504/4885 |
| US-10150767-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | SLC6A2 2892/4885SLC6A4 4040/4885CCR3 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.